Ray Dalio's PTGX Position Overview
Ray Dalio (via Bridgewater Associates, Lp) currently holds 9,269 shares of Protagonist Therapeutics, Inc. (PTGX) worth $1.14 M, representing 0.00% of the portfolio. First purchased in 2026-Q1, this recently established position has been held for 2 quarters.
Based on recent 13F filings, Ray Dalio has initiated a new position in PTGX, representing a fresh investment thesis on this company. Largest addition occurred in Q2 2026, adding 3,993 shares.
Analysis based on 13F filings available since 2013 Q2
Ray Dalio's Protagonist Therapeutics (PTGX) Holding Value Over Time
Track share changes against reported price movement
Quarterly Protagonist Therapeutics (PTGX) Trades by Ray Dalio
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2026 | +3,993 | Add 75.68% | 9,269 | $122.58 |
| Q1 2026 | +5,276 | New Buy | 5,276 | $105.40 |
Ray Dalio's Protagonist Therapeutics Investment FAQs
Ray Dalio first purchased Protagonist Therapeutics, Inc. (PTGX) in Q1 2026, acquiring 5,276 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Ray Dalio has held Protagonist Therapeutics, Inc. (PTGX) for 2 quarters since Q1 2026.
Ray Dalio's largest addition to Protagonist Therapeutics, Inc. (PTGX) was in Q1 2026, adding 5,276 shares worth $556,090.
According to the latest 13F filing for Q2 2026, Ray Dalio's firm, Bridgewater Associates, Lp, owns 9,269 shares of Protagonist Therapeutics, Inc. (PTGX), valued at approximately $1.14 M.
As of the Q2 2026 filing, Protagonist Therapeutics, Inc. (PTGX) represents approximately 0.00% of Ray Dalio's publicly disclosed stock portfolio, making it one of their key holdings.
Ray Dalio's peak holding in Protagonist Therapeutics, Inc. (PTGX) was 9,269 shares, as reported at the end of Q2 2026.